Jay Tanna
George Washington University
16 Papers
1 Citations
Jay Tanna is an academic researcher from George Washington University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT
Hannah Kinoshita,Kenneth R. Cooke,Melanie Grant,Maja Stanojevic,Conrad Russell Y. Cruz,Michael A. Keller,Maria Fernanda Fortiz,Fahmida Hoq,Haili Lang,J Barrett,Hua Liang,Jay Tanna,Ning Zhang,Abeer Shibli,Anushree Datar,K. Fulton,Divyesh Kukadiya,Anqing Zhang,Kirsten M. Williams,Hema Dave,Jeffrey S. Dome,David A. Jacobsohn,Patrick J. Hanley,Richard J. Jones,Catherine M. Bollard +24 more
TL;DR: Donor-derived, tumor-associated, antigen-specific T cells targeting survivin, PRAME, and WT1 are safe in acute leukemia patients post-BMT, and 90% of evaluable high-risk patients were alive at 1 year.
Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells.
TL;DR: The unique tests associated with ex vivo-expanded tumor-associated antigen T cells (TAA-T) include functional assays to determine potency, specificity, and identity, tests for pathogenic contaminants, such as bacteria and fungus as well as other contaminants such as Mycoplasma and endotoxin, and recommendations for critical quality attributes and parameters associated with the expansion of TAA-Ts.
12
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease
Hannah Kinoshita,Mamatha Mandava,Mariah Jensen-Wachspress,Haili Lang,Elisabeth Joy,Jay Tanna,Chase D. McCann,S. O'Brien,Sianna Burnett,Abeer Shibli,Fahmida Hoq,Monica Bhatia,Patrick J. Hanley,Blachy J. Dávila Saldaña,Kris Michael Mahadeo,Catherine M. Bollard,Michael A. Keller,Allistair Abraham +17 more
TL;DR: In this article , the authors showed that virus-specific T cells are safe in patients with SCD following hematopoietic stem cell transplant, and that 80% achieved remission of at least 1 target virus.
Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
Catherine Lindgren,Ashley S. Leinbach,Julie Annis,Jay Tanna,Nan Zhang,Jonathan H. Esensten,Patrick J. Hanley +6 more
TL;DR: Based on the collective experience of the Consortium for Pediatric Cellular Immunotherapy, the authors summarize the challenges encountered by institutions in shipping and receiving the starting material and final product as well as preparing the final product for infusion.
5
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment
Michael D Keller,Patrick J. Hanley,Yueh-Yun Chi,Paibel Aguayo-Hiraldo,Christopher C Dvorak,Michael R. Verneris,Donald B. Kohn,Sung-Yun Pai,Blachy J. Dávila Saldaña,Benjamin Hanisch,Troy C. Quigg,Roberta H Adams,Ann Dahlberg,Shanmuganathan Chandrakasan,Hasibul Hasan,Jemily Malvar,Mariah Jensen-Wachspress,Chris Lazarski,Gelina M. Sani,John M Idso,Haili Lang,Pamela Chansky,Chase D McCann,Jay Tanna,Allistair Abraham,Jennifer L Webb,Abeer Shibli,Amy E. Keating,Prakash Satwani,Pawel Muranski,E. Hall,Michael J. Eckrich,Evan Shereck,Holly Miller,Ewelina Mamcarz,Rajni Agarwal,Satiro N. De Oliveira,Mark Vander Lugt,Christen L. Ebens,Victor Aquino,Jeffrey J. Bednarski,Julia I. Chu,Suhag Parikh,Jennifer Whangbo,Michail S. Lionakis,Elias T. Zambidis,Elizabeth Gourdine,Catherine M. Bollard,Michael A. Pulsipher +48 more
TL;DR: Key clinical factors that impact response to VSTs are highlighted and the feasibility and efficacy of this therapy in pediatric HSCT are demonstrated.
3